Does Tufts Health Plan Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that drive type-2 inflammatory responses. The FDA has approved dupilumab for six distinct indications as of early 2025: moderate-to-severe atopic dermatitis, moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, and COPD with eosinophilic inflammation. [1] [2]

Why Insurers Apply Strict Controls

Because Dupixent carries a wholesale acquisition cost near $4,000 per month, commercial payers and managed Medicaid plans almost universally place it on a specialty tier and require prior authorization. The drug does not have a generic equivalent. Step therapy requirements reflect insurer efforts to ensure lower-cost first-line agents have been tried before a high-cost biologic is authorized.

The clinical evidence supporting dupilumab is strong. In the SOLO 1 and SOLO 2 trials (combined N=671), 16 weeks of dupilumab 300 mg every two weeks produced an IGA 0/1 response in 36 to 38% of patients versus 8 to 10% on placebo (P<0.001). [3] The LIBERTY AD CHRONOS trial (N=740) extended those findings to 52 weeks, showing sustained efficacy with acceptable safety. [4]

Tufts Health Plan Plan Types That Affect Coverage

Tufts Health Plan operates several distinct product lines, including commercial HMO and PPO plans, Tufts Health Public Plans (MassHealth and ConnectorCare), Tufts Medicare Preferred (HMO and supplement), and employer self-funded plans administered by Tufts. Coverage rules differ across these products. A commercial PPO formulary may place Dupixent on Tier 4 or Tier 5 specialty, while a MassHealth-contracted plan follows Massachusetts Medicaid Drug List policies separately. Always verify the specific plan document or call the number on the back of the member ID card.

Prior Authorization: What Tufts Typically Requires

Prior authorization (PA) is mandatory for Dupixent across Tufts Health Plan lines. The PA process protects the member from unexpected cost, but it adds a step between prescription and dispensing.

Standard PA Criteria for Atopic Dermatitis

For moderate-to-severe atopic dermatitis, Tufts (and most commercial payers following ICER and AAD guidance) generally requires:

• A confirmed diagnosis of moderate-to-severe atopic dermatitis, typically documented with an IGA score of 3 or 4 or a SCORAD/EASI score in the moderate-to-severe range. [5]
• Documentation that the patient has tried and failed, or has a contraindication to, at least one conventional systemic agent such as methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil, or that topical therapies (medium-to-high potency corticosteroids plus a topical calcineurin inhibitor) have been inadequate.
• Confirmation that the prescriber is a board-certified dermatologist or allergist, or that a specialist has been consulted.
• Age-appropriate dosing consistent with the FDA label. [1]

The AAD-NPF guidelines published in the Journal of the American Academy of Dermatology recommend dupilumab as a first-line systemic agent for adults with moderate-to-severe AD who are candidates for systemic therapy, citing a favorable benefit-risk profile. [5]

PA for Asthma, CRSwNP, EoE, and Prurigo Nodularis

Each additional indication carries its own PA checklist:

• Asthma: Peripheral eosinophil count ≥150 cells/mcL at initiation or ≥300 cells/mcL in the past year, plus inadequate control on an inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination. The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab 200 mg or 300 mg every two weeks reduced severe exacerbations by 47.7% versus placebo in patients with baseline eosinophils ≥300 cells/mcL. [6]
• CRSwNP: Prior nasal corticosteroid therapy and documentation of bilateral polyps on nasal endoscopy or CT scan.
• EoE: Diagnosis confirmed by esophageal biopsy showing ≥15 eosinophils per high-power field, with prior proton pump inhibitor trial. The Phase 3 LIBERTY-EoE TREET trial (N=321) demonstrated histologic remission in 59% of dupilumab-treated patients versus 6% placebo at 24 weeks (P<0.001). [7]
• Prurigo nodularis: Confirmed diagnosis and prior failure of at least one topical or systemic therapy.

How to Submit the PA to Tufts Health Plan

Prescribers submit PA requests through Tufts Health Plan's online provider portal, by fax, or via a specialty pharmacy's hub service such as the Dupixent MyWay program. Required documents typically include:

1. Completed PA request form with ICD-10 diagnosis code
2. Clinic notes documenting disease severity scoring
3. Records of prior therapy trials and outcomes
4. Proposed dosing and duration

Tufts is required by Massachusetts law to issue standard PA decisions within three business days of receiving a complete request, and urgent decisions within 24 hours. [8]

Formulary Placement and What You Will Actually Pay

Dupixent sits on the specialty tier (typically Tier 4 or Tier 5) of Tufts commercial formularies. Specialty tier cost-sharing varies dramatically by employer plan design.

Typical Commercial Cost-Sharing Ranges

Without assistance, a commercially insured Tufts member might face:

• A specialty copay of $150, $500 per fill, or
• A coinsurance of 20 to 33% of the negotiated specialty drug cost.

Because the negotiated cost of Dupixent can exceed $3,500 per monthly fill, a 20% coinsurance produces a patient liability near $700 per month before any assistance. That figure drops sharply with the Dupixent MyWay copay card (see below).

Medicare Part D Coverage Through Tufts Medicare Preferred

Under Medicare Part D, Dupixent is covered on specialty tiers of Tufts Medicare Preferred plans. The Inflation Reduction Act capped Medicare Part D out-of-pocket drug costs at $2,000 per year starting January 1, 2025, which meaningfully reduces the annual burden for Medicare members who previously hit the catastrophic coverage threshold. [9] Dupixent's manufacturer copay card cannot be used for Medicare beneficiaries, but the Dupixent Patient Assistance Program (Sanofi Cares) offers income-based support.

MassHealth / Medicaid Coverage

Massachusetts MassHealth (Medicaid) covers dupilumab under its Pharmacy program for members who meet the state drug list criteria. MassHealth does not have a formulary tier copay structure in the traditional sense; instead, state-employed clinical pharmacists review PA requests against the MassHealth Clinical Criteria. Members with MassHealth Standard generally pay $3.65 per fill under the state's cost-sharing limits.

The Dupixent MyWay Program: Reducing Commercial Patient Costs

Sanofi and Regeneron operate the Dupixent MyWay patient support program. For commercially insured patients (not Medicare or Medicaid), the copay card can reduce out-of-pocket cost to $0 per month, subject to an annual cap (currently up to $13,000 per calendar year for eligible patients). [10]

Who Qualifies for Dupixent MyWay

Eligibility requires:

• Commercial (private) insurance that covers Dupixent
• Residence in the United States
• Not enrolled in a federal or state government payer (Medicare, Medicaid, CHIP, TRICARE, or VA)
• Household income may be assessed for patient assistance (separate from the copay card)

Patients enroll online at the Dupixent MyWay website or by calling 1-844-DUPIXENT. The specialty pharmacy dispenses Dupixent and bills the copay card directly in most cases.

Patient Assistance for the Uninsured or Underinsured

For patients who do not qualify for the copay card (including Medicare beneficiaries), Sanofi Cares provides free medication to patients meeting income thresholds. The program generally serves patients with household incomes at or below 600% of the federal poverty level, though criteria may be updated annually.

What to Do If Tufts Denies Your Dupixent Prior Authorization

Denials happen. A denial letter from Tufts Health Plan must include the specific clinical reason for denial and instructions for appeal. Massachusetts law grants members the right to an internal appeal, followed by an external review by an independent organization if the internal appeal fails.

Step 1: Internal Appeal

File a written internal appeal within 30 days of the denial (or per the timeframe stated in your denial letter). Submit:

• A letter from your dermatologist or specialist explaining medical necessity
• Published clinical guidelines, such as the AAD-NPF recommendations or GINA guidelines for asthma [11]
• Peer-reviewed evidence, including relevant trial data
• Records documenting severity and prior treatment failures

The AAD's Position Statement on step therapy notes that insurers should not require patients to try and fail medications that are contraindicated or clinically inappropriate. [5]

Step 2: Urgent or Expedited Appeal

If your condition poses a serious health risk without the medication, request an expedited appeal. Tufts must respond within 72 hours to expedited internal appeals under Massachusetts Division of Insurance rules. [8]

Step 3: External Independent Review

If the internal appeal is denied, Massachusetts law requires the insurer to offer an external independent medical review by a state-approved Independent Review Organization (IRO). The IRO decision is binding on Tufts Health Plan. The Massachusetts Health Insurance Consumer Assistance Program (HICAP) can help members manage this process at no cost.

Step 4: Massachusetts Division of Insurance Complaint

If you believe the denial was improper, file a complaint with the Massachusetts Division of Insurance online. Documented complaints can prompt regulatory review of the plan's PA practices.

Monitoring Requirements and Ongoing Authorization

Dupixent prior authorizations are not permanent. Tufts typically issues authorizations for six to twelve months, requiring a renewal PA to continue therapy.

What Renewal PA Typically Requires

Renewal submissions should include updated physician notes documenting:

• Response to therapy (IGA score improvement, reduction in itch/NRS scores, exacerbation frequency for asthma)
• Absence of significant adverse events
• Continued medical necessity

The FDA label for dupilumab notes that efficacy was maintained through 52 weeks in the CHRONOS trial and through 16 weeks in each of the other key trials. [1] Demonstrating documented clinical benefit is the clearest path to renewal approval.

Monitoring for Side Effects Relevant to Payer Review

Common adverse events with dupilumab include injection-site reactions (occurring in approximately 10% of patients in key trials) and conjunctivitis (occurring in 10 to 28% of atopic dermatitis patients in long-term studies). [12] If conjunctivitis develops, ophthalmology co-management is recommended. Payers may occasionally request documentation that side effects are managed appropriately as part of renewal.

Biosimilar Field and Future Cost Implications

No FDA-approved biosimilar to dupilumab exists as of early 2025. Sanofi and Regeneron hold composition-of-matter and method-of-treatment patents on dupilumab that extend into the early 2030s. When biosimilars do enter the market, insurers including Tufts are likely to apply non-medical switching policies that could require patients to try the biosimilar before the reference product. Tracking the FDA's biosimilar pipeline at accessdata.fda.gov is worthwhile for patients on long-term dupilumab therapy. [13]

Dupixent Dosing by Indication: Why It Matters for Coverage

Payers match the authorized dose to the FDA-approved label. Submitting a dose outside the label is a common reason for PA denial.

Approved Dosing Summary

| Indication | Starting Dose | Maintenance Dose | |---|---|---| | Atopic dermatitis (adult) | 600 mg SC (two 300 mg injections) | 300 mg SC every 2 weeks | | Atopic dermatitis (child 6 to 17, ≥60 kg) | 600 mg SC | 300 mg SC every 2 weeks | | Atopic dermatitis (child 6 to 17, 30 to 59 kg) | 400 mg SC | 200 mg SC every 2 weeks | | Atopic dermatitis (6 mo, 5 yr, 15 to 29 kg) | 300 mg SC | 300 mg SC every 4 weeks | | Moderate-severe asthma (adult) | 400 mg SC | 200 mg SC every 2 weeks | | CRSwNP (adult) | 300 mg SC | 300 mg SC every 2 weeks | | EoE (adult/adolescent ≥12 yr) | 300 mg SC | 300 mg SC every week | | Prurigo nodularis (adult) | 600 mg SC | 300 mg SC every 2 weeks | | COPD (adult, eosinophilic) | 300 mg SC | 300 mg SC every 2 weeks |

Source: FDA prescribing information, dupilumab. [1]

Practical Tips for Getting Dupixent Approved Through Tufts

Speed and completeness of documentation are the factors most under the prescriber's and patient's control.

Tips for Prescribers

• Use objective severity scores in every note. IGA, EASI, SCORAD, ACQ, or NRS scores give the PA reviewer quantitative evidence rather than narrative description alone.
• Document each prior therapy trial with start date, duration, dose, and reason for failure or discontinuation.
• Reference specific guideline language. Quoting the AAD-NPF recommendation that dupilumab is appropriate "for adult patients with moderate-to-severe AD who are candidates for systemic therapy" carries weight in PA submissions. [5]
• Submit the PA concurrently with the prescription to avoid dispensing delays.

Tips for Patients

• Ask the prescriber's office to use the Dupixent MyWay hub, which employs patient support liaisons who manage PA submission, appeals, and copay card enrollment simultaneously.
• Keep copies of all PA correspondence, including fax confirmation pages.
• If denied, call Tufts Member Services (the number on your ID card) within one business day to request the specific clinical criteria used in the denial.
• Request a peer-to-peer review. Most commercial payers, including Tufts managed care products, allow the prescribing physician to speak directly with the reviewing medical director before or after a denial.

Peer-to-peer reviews resolve a meaningful proportion of initial denials without requiring a formal appeal, particularly when the prescriber can present real-time clinical data and reference current guidelines published by the FDA [1], AAD [5], and GINA. [11]

Patients enrolled in Tufts Health Public Plans should contact their plan's Member Services line and ask specifically whether the clinical criteria published in the MassHealth Drug List bulletin for dupilumab have been updated in the current calendar year, since Massachusetts periodically revises its coverage criteria in response to new FDA approvals and emerging clinical data.